Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Abstract Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe
endocrine disease caused by a corticotroph pituitary tumor and associated with increased …

Background Many patients with acromegaly do not achieve biochemical control despite
receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide …

Abstract In March 2011, the Acromegaly Consensus Group met to revise and update the
guidelines on the diagnosis and treatment of acromegaly complications. The meeting was …

The WHO categorizes pituitary tumours as typical adenomas, atypical adenomas and
pituitary carcinomas, with typical adenomas constituting the major class. However, the WHO …

Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and
lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical …

Acromegaly is characterized by increased release of growth hormone and, consequently,
insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to …

Background Most pituitary neuroendocrine tumors (PitNETs) show benign behavior, but a
substantial number are invasive, recur, or resist medical treatment. Based on a retrospective …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …